Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

117.41
+1.981.72%
Volume:343.81K
Turnover:40.43M
Market Cap:9.76B
PE:-36.55
High:119.59
Open:116.03
Low:114.35
Close:115.43
52wk High:130.05
52wk Low:43.74
Shares:83.15M
Float Shares:64.87M
Volume Ratio:0.59
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.47
PE(LYR):-31.82

Loading ...

Wolfe upgrades Kymera Therapeutics to Outperform on potential upside

TIPRANKS
·
Yesterday

Kymera Therapeutics Raised to Outperform from Peer Perform by Wolfe Research

Dow Jones
·
Yesterday

J.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

TIPRANKS
·
Sep 04

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire
·
Sep 03

Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

MT Newswires Live
·
Sep 02

U.S. Research Roundup-Adobe, Dell Technologies, Zscaler

Reuters
·
Sep 02

Kymera Therapeutics, Inc. : JP Morgan Raises Target Price to $140 from $121

THOMSON REUTERS
·
Sep 02

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral Stat6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

THOMSON REUTERS
·
Sep 01

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

GlobeNewswire
·
Sep 01

Kymera Therapeutics Price Target Raised to $151.00/Share from $116.00 by Wells Fargo

Dow Jones
·
Aug 27

Kymera Therapeutics Speeds Pipeline Amid Rising Spend

TIPRANKS
·
Aug 21

Kymera Therapeutics on Track for Record High Closing

Dow Jones
·
Aug 17

Kymera Therapeutics (KYMR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 13

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

TIPRANKS
·
Aug 11

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis

TIPRANKS
·
Aug 06

Kymera Therapeutics, Inc. : Citigroup Raises Target Price to $135 from $120

THOMSON REUTERS
·
Aug 06

Kymera Therapeutics price target raised to $139 from $133 at Barclays

TIPRANKS
·
Aug 06